MSH3 and neoplasm: MKI67, SYNE1, PCLO, MSH3, RECQL4, NOTCH2, ILR7, CIITA, LRRK2, and EML4 genes were frequently mutated in patients who respond to CROSS regimen with the tumor mutation count significantly decreased from pre- to post-treatment tumor samples.